Methylphenidate patch, liquids and other forms: which are approved for adults

Methylphenidate comes in many forms: a skin patch, a liquid, chewable tablets, a tablet that melts on the tongue, an evening capsule and several once-daily tablets and capsules. Many of these were developed for children who cannot swallow pills, and their FDA labels reflect that. Some cover adults; several do not. This page lists the less familiar forms with what each current label says about age, checked on DailyMed on October 19, 2026. Ritalin, Concerta and Focalin have their own pages. Nothing here gives doses or recommends a product.

Why the age wording matters

Each label's indication section states the condition and the ages the FDA reviewed. Three patterns appear below. Some labels name adults outright. Some say "6 years and older" or list ADHD with no age limit, which includes adults within the wording even when the trials were in children. Others stop at a specific age, such as 12, 15 or 17. For those, prescribing to an adult is off-label: legal, sometimes reasonable, but outside what the FDA reviewed. It is fair to ask why such a product was chosen. ADHD medications approved for adults in 2026 covers all classes.

The forms at a glance

All of these contain methylphenidate, a Schedule II controlled substance, and carry the class boxed warning on abuse, misuse and addiction that the FDA updated for all prescription stimulants in May 2023.

The patch: Daytrana

Daytrana is a methylphenidate transdermal system. Its label limits the indication to "pediatric patients 6 to 17 years of age," and the generic patch label checked for this guide has the same wording, so adult use is off-label. The label describes applying the patch to the hip, alternating sides, about 2 hours before an effect is needed and removing it 9 hours after application, or earlier if a shorter effect is wanted.

The patch has warnings that pills do not:

• Chemical leukoderma: a lasting loss of skin color at and around the application site, sometimes at distant sites. The label says to stop the patch if it occurs.
• Contact sensitization: redness is common, but a more intense reaction (swelling, bumps, blisters) that does not improve within 48 hours or spreads beyond the patch site suggests sensitization.
• External heat: heating pads and similar sources on the patch significantly increase how fast and how much drug is absorbed.

The evening capsule: Jornay PM

Jornay PM is the one methylphenidate product the label says "should be taken only in the evening." Its beads have an outer delayed-release coating and an inner extended-release coating, and the label describes adjusting the evening timing for effect the next morning and through the day. The label says to take it consistently with or without food, and the capsule may be opened and sprinkled on applesauce. The indication covers "patients 6 years and older." Its efficacy trials were in children 6 to 12, supported by pharmacokinetic data in adults. Based on other methylphenidate products, the label lists the most common reactions for adults and children as decreased appetite, insomnia, nausea, vomiting, indigestion, abdominal pain, weight loss, anxiety, dizziness, irritability, mood swings, fast heart rate and increased blood pressure.

Osmotic tablets: Relexxii

Relexxii uses osmotic pressure to release methylphenidate at a controlled rate, similar in design to Concerta. Its label covers "adults (up to the age of 65 years) and pediatric patients 6 years of age and older." The most common adult side effects were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight loss, irritability and sweating. Like Concerta, the tablet shell can pass in the stool. See Concerta for adults.

Liquids and chewables

• Methylin oral solution is an immediate-release liquid labeled for "adults and pediatric patients 6 years of age and older," and for narcolepsy.
• Quillivant XR is an extended-release powder that is mixed with water to make a liquid; the label says to shake the bottle vigorously before each dose. Its indication lists ADHD with no age range, and its efficacy study was in children 6 to 12.
• QuilliChew ER is an extended-release chewable tablet. Its indication also lists ADHD without an age range, its dosing section refers to "patients 6 years and above," and its efficacy study was in children 6 to 12.
• Cotempla XR-ODT dissolves in the mouth. The label says to keep it in the blister pack until just before taking it, with dry hands. It is labeled for ages 6 to 17 only.

Discontinued products

FDA's Drugs@FDA database lists Adhansia XR, a methylphenidate extended-release capsule, and brand Ritalin-SR tablets as discontinued. Older articles still mention both. Generic methylphenidate extended-release tablets of the Ritalin-SR type remain on the market and are labeled for adults, as explained in Ritalin for adults.

Shared warnings and contraindications

Across these labels, methylphenidate is contraindicated with known hypersensitivity to it and with a monoamine oxidase inhibitor (MAOI) now or within 14 days. Shared warnings cover serious heart disease, blood pressure and heart rate, psychiatric effects including mania and psychosis, priapism, circulation problems in fingers and toes, glaucoma and tics. See side effects in adults and drug interactions.

Pregnancy and breastfeeding

The labels point to the National Pregnancy Registry for ADHD Medications. Their lactation sections report that methylphenidate passes into milk in small amounts with no reported harm to infants, unknown long-term effects, and advice to watch the infant for agitation, poor sleep, poor feeding and reduced weight gain. LactMed summarizes the research; ADHD in pregnancy and postpartum covers decisions in more depth.

Supply and cost

As of mid-October 2026, FDA's drug shortage database listed methylphenidate extended-release tablets among current shortages, and it also listed the methylphenidate extended-release film (the patch) as a current shortage, first posted February 28, 2025. Some specialty forms may not be on a plan's preferred list, so it helps to ask the plan and pharmacy before a prescription is written. ADHD medication shortages explains lawful options when a pharmacy is out.

New York and New Jersey rules

Every form here is Schedule II, so prescriptions cannot be refilled in either state. New York limits a prescription to a 30-day supply unless it is written for a condition the state allows up to three months for, which includes attention deficit disorder (New York's rules). New Jersey limits each prescription to 30 days, with multiple dated prescriptions up to 90 days, and since July 8, 2026 requires an in-person visit within 30 days for adults located in New Jersey who start a Schedule II stimulant by telehealth (New Jersey's rules).

Questions to ask your prescriber

• Does this product's label cover my age, and if not, why is it the right choice for me?
• I have trouble swallowing pills. Which adult-labeled options can be opened, sprinkled or taken as a liquid?
• Would an evening-dosed product help with mornings?
• Will my plan cover a brand-only form?

Dr. Shershow evaluates adults for ADHD and, when medication is appropriate, manages it over time. See adult ADHD treatment.